Cite

HARVARD Citation

    Choi, J. et al. (2018). A PI3K p110α-selective inhibitor enhances the efficacy of anti-HER2/neu antibody therapy against breast cancer in mice. Oncoimmunology. p. . [Online]. 
  
Back to record